Main objectives

▪ To drug screen PDOs using high-throughput robotic method for an estimate of 175-345 patients.

▪ To interpret and classify PDO drug sensitivity.

▪ To provide a personalized report in a timely manner to inform oncologists and orientate patient treatment.